Engene Therapeutics Inc Revenue Growth Rates (ENGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Engene Therapeutics Inc   (NASDAQ: ENGN)
 

ENGN's Revenue Growth by Quarter and Year

Engene Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter October -
3rd Quarter July 0.00
2nd Quarter April 0.00
1st Quarter January 0.00
FY 0.00





ENGN Revenue third quarter 2026 Y/Y Growth Comment
Engene Therapeutics Inc in the third quarter 2026 recorded of $ 0.00 millions.

According to the results reported in the third quarter 2026, Engene Therapeutics Inc achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Engene Therapeutics Inc ' s Revenue no change of 0% ranks overall at the positon no. in the third quarter 2026.


ENGN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter October - - - -
3rd Quarter July - - - -
2nd Quarter April - - - -
1st Quarter January - - - -
FY   - - - -

Financial Statements
Engene Therapeutics Inc 's third quarter 2026 Revenue $ 0.00 millions ENGN's Income Statement
Engene Therapeutics Inc 's third quarter 2025 Revenue $ 0.00 millions Quarterly ENGN's Income Statement


ENGN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter October - - - -
3rd Quarter July - - - -
2nd Quarter April - - - -
1st Quarter January - - - -
FY (Year on Year)   - - - -


Back to ENGN Growth rate Comparisons >> Back to ENGN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Engene Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENGN's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENGN's III. Quarter Q/Q Revenue Comment


Engene Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jul 31 2026)		 12 Months Ending
(Apr 30 2026)		 12 Months Ending
(Jan 31 2026)		 12 Months Ending
(Oct 31 2025)		 12 Months Ending
(Jul 31 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jul 31 2026 period, Engene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Engene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jul 31 2026 period, Engene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Engene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENGN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Jul 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jul 31 2026
Lakeland Industries Inc -4.49%$ -4.490 millions
Kewaunee Scientific Corporation-6.50%$ -6.499 millions
Nutriband Inc -29.71%$ -29.711 millions


About Engene Therapeutics Inc Revenue Growth Rates (ENGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Engene Therapeutics Inc (CIK 1980845).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-384383
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Engene Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.